Tezspire is 210 units for use of one prefilled syringe of Tezspire.
Tezspire is injected in the front of the thigh or the lower part of the stomach.
Tezspire is a priority review and was the first and only biologic to be granted priority review in the US for the treatment of asthma by the FDA.
Tezspire begins working the same day you get the injection although it can take several weeks and sometimes months to notice a significant improvement in your asthma symptoms once you begin taking Tezspire.
Most people see a reduction in their asthma symptoms as soon as 2 weeks after the first injection of Tezspire.
Tezspire came out in December 2021 when it was FDA approved.
Tezspire is owned and jointly developed by AstraZeneca and Amegen.
The type of asthma that Tezspire treats is uncontrolled severe asthma that is not controlled by other medications or treatments.
The recommended dose of TEZSPIRE is 210 mg administered subcutaneously once every 4 weeks.
If a dose is missed, administer the dose as soon as possible.
The criteria for Tezspire is you will be required to have at least a history of 2 or more asthma exacerbations that require injectable or oral corticosteroid treatment or 1 asthma exacerbation that results in hospitalization in the past twelve months.
You can store Tezspire at room temperature between 68 F to 77 F or refrigerate Tezspire at 36 F to 42 F.
Tezspire is not a pill and instead Tezspire is an injection medicine which is injected under your skin once a month by a doctor or at home after proper instruction.
Tezspire is FDA approved and was FDA approved in December 2021.
People who should not take Tezspire are people who are allergic to tezepelumab or any of the ingredients in Tezspire.
You can qualify for Tezspire when you have a history of 2 or more asthma exacerbations that require injectable or oral corticosteroid treatment or 1 asthma exacerbation that results in hospitalization in the past 12 months.
Tezspire costs $3,847.35 per 210 mg/mL.
Tezspire injection is not a steroid but instead is a type of biologic drug called a monoclonal antibody.
The biologic drugs are made from living cells and the monoclonal antibodies block activity of certain proteins in the body.
Tezspire medication is a medication that treats severe asthma and reduces inflammation.
Because Tezspire medication reduces inflammation in the airways, Tezspire makes the breathing easier and reduces symptoms of asthma which improves your lung function and also helps to prevent asthma attacks.
The adverse reactions to Tezspire include trouble breathing, severe dizziness, rash, itching and swelling of the face, tongue and throat.
If you notice any of these adverse and serious reactions to Tezspire you should seek medical attention right away.
The generic name for Tezspire is Tezepelumab-ekko.
Tezspire is not available in a biosimilar form. (Biosimilars are like generic drugs.
But unlike generics, which are made for non-biologic drugs, biosimilars are made for biologic drugs.)
Instead, tezepelumab-ekko comes only as the brand-name drug Tezspire.
The drug Tezspire is a treatment for severe asthma that proactively reduces inflammation, which means you could experience: Fewer asthma attacks.
Better breathing and improved lung function and improved asthma symptom control.
The cost for Tezspire subcutaneous solution (ekko 210 mg/1.91 mL) is around $4,061.00 for a supply of 1.91 milliliters, depending on the pharmacy you visit.
The Patient Assistance Program provides TEZSPIRE to qualified patients at no cost.
Eligible patients must meet certain requirements including being uninsured or underinsured on Medicare Part B without supplemental insurance or on Medicare Advantage with an affordability gap.
Do not take TEZSPIRE if you are allergic to tezepelumab or any of the ingredients in TEZSPIRE.
The most common side effects of TEZSPIRE include: Sore throat (pharyngitis) Joint pain (arthralgia)
Other side effects of Tezpire include.
Back pain.
Body aches or pain.
Cough.
Difficulty in moving.
Dryness or soreness of the throat.
Fever.
Muscle pain or stiffness.
Redness, pain, or itching at the injection site.
Although Tezspire begins working shortly after your first dose, it's likely to take several weeks or even months before you notice your symptoms begin to ease.
However some people receiving Tezspire in studies saw a reduction in their asthma symptoms as soon as 2 weeks after the first dose.
The recommended dosage of TEZSPIRE is 210 mg administered subcutaneously once every 4 weeks.
If a dose is missed, administer the dose as soon as possible.
Thereafter, the patient can continue (resume) dosing on the usual day of administration.
If the next dose is already due, then administer as planned.